Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-4106 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 (Dose Escalation): mRNA-4106 Alone | EXPERIMENTAL | Participants will receive mRNA-4106 at a test dose as monotherapy. |
| Arm 2 (Dose Escalation): mRNA-4200 Alone and in Combination with Pembrolizumab | EXPERIMENTAL | Participants will receive mRNA-4200 as monotherapy, followed by mRNA-4200 in combination with pembrolizumab, and continuation of pembrolizumab alone. |
| Name | Type | Description |
|---|---|---|
| mRNA-4106 | BIOLOGICAL | Intramuscular injection |
| Pembrolizumab | BIOLOGICAL | Intravenous infusion |
| mRNA-4200 | BIOLOGICAL | Intramuscular injection |
Key Inclusion Criteria: * Arm 1: Histologically confirmed advanced or metastatic cancer (cutaneous melanoma, non-small cell lung cancer \[NSCLC\], hepatocellular carcinoma \[HCC\], esophageal carcinoma, head and neck squamous cell carcinoma \[HNSCC\], colon/rectal adenocarcinomas, urothelial/bladde...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
mRNA-4106 is an investigational RNA therapy being developed by Moderna, Inc. for the treatment of advanced solid tumors. It is in Phase 1 clinical development and is being studied both as a single agent and in combination with anti-cancer agents. mRNA-4106 has not been approved by the FDA.
mRNA-4106 is being studied for use in advanced solid tumors. The Phase 1 trial enrolls adults 18 years and older with solid tumors, and the study is taking place in the United States. mRNA-4106 is investigational and has not been approved for any indication.
mRNA-4106 is being developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is the sponsor of the Phase 1 study evaluating mRNA-4106 alone or in combination with anti-cancer agents in participants with solid tumors.
mRNA-4106 is in Phase 1 clinical development. One Phase 1 trial is currently recruiting, and no trials of mRNA-4106 have been completed. The program remains investigational, and mRNA-4106 has not received FDA approval.
mRNA-4106 is being evaluated in one Phase 1 trial, NCT06880549, titled A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors. The trial is recruiting in the United States and plans to enroll 42 participants aged 18 years and older.
mRNA-4106 is being tested both as a single agent and in combination with anti-cancer agents. The Phase 1 trial NCT06880549 uses a controlled design and enrolls 42 participants with advanced solid tumors. It is not randomized or double blinded, and participants are not selected by biomarker.